Meeting
2013 ASCO Annual Meeting
A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905).
Authors
Anne S. Tsao
The University of Texas MD Anderson Cancer Center, Houston, TX
Anne S. Tsao , James Moon , Ignacio Ivan Wistuba , Nicholas J. Vogelzang , Gregory Peter Kalemkerian , Mary Weber Redman , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT01064648
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7527)
DOI
10.1200/jco.2013.31.15_suppl.7527
Abstract #
7527
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
First Author: Anne S. Tsao
Poster
2017 ASCO Annual Meeting
Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).
First Author: Melissa Phillips
Poster
2016 ASCO Annual Meeting
18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin.
First Author: Peter Wojciech Szlosarek
Poster
2015 ASCO Annual Meeting
Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.
First Author: Peter Wojciech Szlosarek